NASDAQ: PCVX
Vaxcyte Inc Stock

$30.65+1.53 (+5.25%)
Updated Apr 17, 2025
PCVX Price
$30.65
Fair Value Price
$2.60
Market Cap
$3.95B
52 Week Low
$27.66
52 Week High
$121.06
P/E
-8.07x
P/B
1.19x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$463.93M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.06
Operating Cash Flow
-$453M
Beta
0.8
Next Earnings
May 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A

PCVX Overview

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine PCVX's potential to beat the market

DSell
  • Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More

Zen Rating Component Grades

B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
PCVX
Ranked
#317 of 463

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important PCVX news, forecast changes, insider trades & much more!

PCVX News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PCVX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

PCVX ($30.65) is overvalued by 1,080.43% relative to our estimate of its Fair Value price of $2.60 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PCVX ($30.65) is not significantly undervalued (1,080.43%) relative to our estimate of its Fair Value price of $2.60 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PCVX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PCVX due diligence checks available for Premium users.

Valuation

PCVX fair value

Fair Value of PCVX stock based on Discounted Cash Flow (DCF)

Price
$30.65
Fair Value
$2.60
Overvalued by
1,080.43%
PCVX ($30.65) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PCVX ($30.65) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PCVX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

PCVX price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-8.07x
Industry
-177.72x
Market
27.98x

PCVX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
1.19x
Industry
4.05x
PCVX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

PCVX's financial health

Profit margin

Revenue
$0.0
Net Income
-$137.1M
Profit Margin
0%
PCVX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$3.5B
Liabilities
$205.5M
Debt to equity
0.06
PCVX's short-term assets ($1.79B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PCVX's short-term assets ($1.79B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PCVX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PCVX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$111.4M
Investing
-$557.2M
Financing
$4.9M
PCVX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

PCVX vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
PCVXD$3.95B+5.25%-8.07x1.19x
RYTMC$3.90B+0.65%-14.23x179.64x
PTCTC$3.74B+2.11%-10.02x-3.40x
ACLXD$3.41B+2.19%-31.01x7.49x
IONSD$4.51B+0.18%-9.34x7.67x

Vaxcyte Stock FAQ

What is Vaxcyte's quote symbol?

(NASDAQ: PCVX) Vaxcyte trades on the NASDAQ under the ticker symbol PCVX. Vaxcyte stock quotes can also be displayed as NASDAQ: PCVX.

If you're new to stock investing, here's how to buy Vaxcyte stock.

What is the 52 week high and low for Vaxcyte (NASDAQ: PCVX)?

(NASDAQ: PCVX) Vaxcyte's 52-week high was $121.06, and its 52-week low was $27.66. It is currently -74.68% from its 52-week high and 10.81% from its 52-week low.

How much is Vaxcyte stock worth today?

(NASDAQ: PCVX) Vaxcyte currently has 128,761,622 outstanding shares. With Vaxcyte stock trading at $30.65 per share, the total value of Vaxcyte stock (market capitalization) is $3.95B.

Vaxcyte stock was originally listed at a price of $26.15 in Jun 12, 2020. If you had invested in Vaxcyte stock at $26.15, your return over the last 4 years would have been 17.21%, for an annualized return of 4.05% (not including any dividends or dividend reinvestments).

How much is Vaxcyte's stock price per share?

(NASDAQ: PCVX) Vaxcyte stock price per share is $30.65 today (as of Apr 17, 2025).

What is Vaxcyte's Market Cap?

(NASDAQ: PCVX) Vaxcyte's market cap is $3.95B, as of Apr 21, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Vaxcyte's market cap is calculated by multiplying PCVX's current stock price of $30.65 by PCVX's total outstanding shares of 128,761,622.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.